Otsuka America Pharmaceutical, Inc.
2440 Research Boulevard
About Otsuka America Pharmaceutical, Inc.Otsuka is a successful, global group of affiliated companies that discovers, develops and markets innovative products. In the U.S., Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal and central nervous systems, and to treat cancer and ophthalmic disorders. Our pharmaceutical products include ABILIFY® (aripiprazole) Tablets and intramuscular injection, IV BUSULFEX® (busulfan) Injection and PLETAL® (cilostazol) Tablets, although we no longer actively market PLETAL. We also have the BreathTek™ Urea Breath Test for H. pylori. We have numerous additional products in our pipeline that are currently under development. We are highly diversified, with pharmaceutical as well as consumer products such as Crystal Geyser Water, NatureMade® Vitamins, Ridge Wines, and diagnostic equipment.
Please visit our website at www.otsuka-us.com for more information.
33 articles with Otsuka America Pharmaceutical, Inc.
Top Experts, Lawmakers and Advocates Come Together to Discuss Policy Solutions to Support Growing Number of Americans Living with Mental Illness
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
The ABILIFY MYCITE System, the first drug-device combination product to be approved by FDA to track drug ingestion, will be integrated into Magellan Health’s mental health provider network
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Gamida Cell today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
The Digital Therapeutics Alliance (DTA) welcomes nine companies to membership
Getting patients to adhere to long-term treatments can be difficult. There are a number of new therapies that will monitor whether or not patients are sticking to their regimen.
Avella announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD).
Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care
Held at Elevate by Psych Congress, a gathering of up-and-coming leaders in mental health care, the event featured some of the most groundbreaking technologies in the mental health marketplace.
Otsuka America Pharmaceutical, Inc. Release: Results Of New Survey Show Nearly Two Thirds Of Surveyed Adults With Major Depressive Disorder (MDD) Who Report Taking Their Medication As Prescribed Still Experience Symptoms At Least Weekly
Otsuka America Pharmaceutical, Inc. Release: FDA Approves Deltoid Injection Site For Abilify Maintena (Aripiprazole) For Extended-Release Injectable Suspension In The Treatment Of Schizophrenia
Otsuka America Pharmaceutical, Inc. And Lundbeck Inc. To Present Data On Investigational Compound Brexpiprazole In Schizophrenia And Major Depressive Disorder At American Psychiatric Association Annual Meeting
H. Lundbeck A/S and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: U.S. FDA Accepts For Review Supplemental New Drug Application For Deltoid Administration Of Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia
European Medicines Agency Accepts Otsuka America Pharmaceutical, Inc.'s Marketing Authorisation Application (MAA) For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. Release: Four-Year Data From Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) To Imatinib In First-Line Treatment Of Adults With Ph+ CP-CML